Cost of Anti-CD38 Monoclonal Antibodies in Combination With Bortezomib, Lenalidomide and Dexamethasone for the Frontline Treatment of Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma in the US

QR Code

Cost of Anti-CD38 Monoclonal Antibodies in Combination With Bortezomib, Lenalidomide and Dexamethasone for the Frontline Treatment of Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma in the US

# Background The efficacy of the combination of bortezomib, lenalidomide, and dexamethasone with daratumumab (DVRd) or isatuximab (IsaVRd) for the frontline treatment of transplant-ineligible (TIE) newly diagnosed multiple myeloma (NDMM) has been demonstrated in clinical trials. However, the treatme...

Full description

Saved in:

Bibliographic Details
Main Authors:	Niodita Gupta-Werner, Vipin Khare, Brian Macomson, Rohan Medhekar
Format:	Article
Language:	English
Published:	Columbia Data Analytics, LLC 2025-07-01
Series:	Journal of Health Economics and Outcomes Research
Online Access:	https://doi.org/10.36469/001c.141714
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Predictors of frontline doublet or triplet regimen initiation in transplant-ineligible newly diagnosed multiple myeloma
by: Matthew J. Pianko, et al.
Published: (2025-12-01)

Efficiency of lenalidomide, bortezomib and prednisone (RVP) in patients with newly diagnosed multiple myeloma
by: K. A. Belousov, et al.
Published: (2019-04-01)

Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma
by: Johan Lund, et al.
Published: (2018-06-01)

Bortezomib-melphalan-prednisone versus lenalidomide-dexamethasone in elderly patients with multiple myeloma: the Real MM phase IV trial
by: Sara Bringhen, et al.
Published: (2025-07-01)

Efficacy of lenalidomide, bortezomib, and prednisolone in patients with relapsed or refractory multiple myeloma
by: T. A. Мitinа, et al.
Published: (2015-12-01)

Bortezomib (Velcade) in combination with dexamethasone eor relapsed or refractory myeloma
by: S. S. Bessmeltsev, et al.
Published: (2022-11-01)

Network Meta-Analysis of Once Weekly Selinexor-Bortezomib-Dexamethasone in Previously Treated Multiple Myeloma
by: Michael Dolph, et al.
Published: (2021-08-01)

Lenalidomide for relapsed or refractory multiple myeloma
by: S. S. Bessmeltsev1, et al.
Published: (2014-07-01)

Results of multiple myeloma treatment with bortezomib
by: T. I. Pospelova, et al.
Published: (2022-11-01)

Efficiency of pomalidomide therapy in patients with multiple myeloma refractory to lenalidomide
by: I. G. Rekhtina, et al.
Published: (2019-04-01)

IMPACT OF LENALIDOMIDE MAINTENANCE DOSAGE ON SURVIVAL OUTCOMES IN MULTIPLE MYELOMA
by: Zeynep Kürüm, et al.
Published: (2025-07-01)

The role of АВС transporters in drug resistance to bortezomib in multiple myeloma
by: L. A. Laletina, et al.
Published: (2019-04-01)

Herpes zoster in multiple myeloma patients during bortezomib treatment
by: I. N. Nazarova, et al.
Published: (2014-07-01)

Prevention and management of bortezomib-induced peripheral neuropathy in patients with multiple myeloma
by: S. V. Semochkin, et al.
Published: (2022-04-01)

Bortezomib neurotoxicity treatment of multiple myeloma: single center experience and literature review
by: N. V. Stepanova, et al.
Published: (2022-11-01)

Bortezomib (velcade) plus melphalan and prednisone in elderly untreated patients with multiple myeloma
by: S. S. Bessmeltsev, et al.
Published: (2022-11-01)

Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials.
by: Bo Yang, et al.
Published: (2013-01-01)

Incidence, characteristics, and treatments of peripheral neuropathy in multiple myeloma patients receiving bortezomib (velcade)
by: S. S. Bessmeltsev, et al.
Published: (2022-11-01)

Bortezomib-induced peripheral neuropathy in patients with multiple myeloma: pain syndrome and psychopathological aspects
by: E. Z. Irugova, et al.
Published: (2025-03-01)

CD200 immune checkpoint expression is associated with inferior outcome in multiple myeloma patients treated with anti-CD38 monoclonal antibodies
by: Djamila Chemlal, et al.
Published: (2025-12-01)

Bortezomib-based Chemotherapy and Bone-marrow Followed by Renal Transplantation in Multiple Myeloma: A Literature Review
by: Jasmine Sethi, et al.
Published: (2025-04-01)

PHA RMA COE CONOMI CAL EVALUATION OF MULTIPLE MYELOMA TREATMENT WITH REVLIMID (LENALIDOMIDE ) IN THE RUSSIAN FEDE RATION
by: R. Yagudina, et al.
Published: (2015-03-01)

Review of the Expert Council “Multiple myeloma: the era of monoclonal antibodies in the treatment of patients with multiple myeloma”
by: M. I. Akhmedov, et al.
Published: (2024-01-01)

Clinical and economic implications of using daratumubab with lenalidomide in the 1st and 2nd lines of therapy for multiple myeloma patients
by: О. I. Ivakhnenko, et al.
Published: (2024-05-01)

Treatment of relapsed or refractory Hodgkin’s lymphoma with lenalidomide combined with PD-1 monoclonal antibody: a case report and literature review
by: Hongjuan Dong, et al.
Published: (2025-07-01)

On the frontlines : coping with the library's problem patrons /
by: Salter, Charles A.
Published: (1988)

THERAPY FOR ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION PATIENTS WHO PRESENT LATE OR ARE INELIGIBLE FOR REPERFUSION
by: M. Cohen, et al.
Published: (2016-01-01)

The system in operation. Frontline news
by: Monika Bogdanowska
Published: (2024-07-01)

Frontline brentuximab vedotin-based therapy for newly diagnosed classical Hodgkin lymphoma: a meta-analysis of randomized controlled trials
by: Yue Yang, et al.
Published: (2025-07-01)

Plasma cell dyscrasia: monoclonal gammopathies, AL-amyloidosis, multiple myeloma Clinical case study
by: V. V. Cherepanova, et al.
Published: (2023-03-01)

The role of bone marrow microenvironment in the progression of multiple myeloma from monoclonal gammopathy of undetermined significance
by: A. S. Khudovekova, et al.
Published: (2021-09-01)

Three-year progression-free survival of a patient with concomitant mucinous adenocarcinoma of the colon with peritoneal dissemination and multiple myeloma who received lenalidomide: a case report
by: Koki Tamai, et al.
Published: (2024-02-01)

Correction: Sgherza et al. Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study. <i>Pharmaceuticals</i> 2025, <i>18</i>, 595
by: Nicola Sgherza, et al.
Published: (2025-06-01)

Lenalidomide and its impact on exanthematous reactions: a case report
by: Cristiana Vieira-Maia, et al.
Published: (2025-04-01)

Frontline therapy combining with intrathecal dexamethasone effectively alleviate immune effector cell-associated neurotoxicity syndrome in pediatric relapsed B-ALL receiving pCAR-19B
by: Lu Cao, et al.
Published: (2025-06-01)

Current and future role of carfilzomib‐based quadruplet combinations as therapy for newly diagnosed multiple myeloma
by: Ola Landgren, et al.
Published: (2025-07-01)

Role of Dexamethasone in Meningitis
by: Siddiqui, Emad uddin, et al.
Published: (2012)

At the Frontlines: Confronting Poverty in Primary Care Medicine
by: Kotwani, Namrata, et al.
Published: (2012)

C. Causinius Schola: an eques in Frontline Politics
by: Federico Santangelo
Published: (2025-07-01)

Cost-Minimization Analysis for Subcutaneous Daratumumab in the Treatment of Newly Diagnosed Multiple Myeloma in Three Gulf Countries
by: Anas Hamad, et al.
Published: (2024-07-01)